Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2021 Filed Mar 30, 2021 22:41 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 1,079 | $251.58 | $271,454.82 |
DisclosureSEC source: 0001127602-21-012361 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,673.3789 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 27, 2021 Filed Mar 30, 2021 22:41 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantCommon Stock | 2,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012361 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,752.3789 F1 · kind: Shares acquired on March 27, 2021, pursuant to a performance award granted on February 12, 2018, relating to performance during the three-year period ended December 31, 2020. Read SEC document |
| March 27, 2021 Filed Mar 30, 2021 22:40 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 687 | $251.58 | $172,835.46 |
DisclosureSEC source: 0001127602-21-012360 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,049.0415 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 27, 2021 Filed Mar 30, 2021 22:40 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantCommon Stock | 2,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012360 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,736.0415 F1 · kind: Shares acquired on March 27, 2021, pursuant to a performance award granted on February 12, 2018, relating to performance during the three-year period ended December 31, 2020. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 16:15 UTC |
Wengel Kathryn EDirector
|
GrantRestricted Stock Unit · Derivative | 603 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012182 · form4.xml · derivative · entry 1 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603 Underlying: Common Stock · 603 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on 3/25/2022. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on 3/25/2022. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionNon-qualified Stock Options · Derivative | 633 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · derivative · entry 11 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,267 Underlying: Common Stock · 633 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F7 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionNon-qualified Stock Options · Derivative | 1,533 | $0.00 Strike: $146.59 | $0.00 |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · derivative · entry 10 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 767 Underlying: Common Stock · 1,533 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F7 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 633 | $182.51 | $115,528.83 |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · nonDerivative · entry 7 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
SaleCommon Stock | 2,317 | $241.51 | $559,589.33 |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · nonDerivative · entry 6 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343.2194 F3 · price: The price of $241.5146 per share represents a weighted average of sales prices ranging from $240.92 to $241.651 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 19:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 1,533 | $146.59 | $224,722.47 |
DisclosureSEC source: 0001127602-21-006676 · form4.xml · nonDerivative · entry 5 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,660.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:28 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 100 | $236.05 | $23,605.00 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 7 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,426.0415 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:28 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 5 | $235.89 | $1,179.45 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 6 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,526.0415 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:28 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 103 | $237.06 | $24,417.18 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 5 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,531.0415 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:27 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 85 | $237.06 | $20,150.10 |
DisclosureSEC source: 0001127602-21-006182 · form4.xml · nonDerivative · entry 6 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339.3789 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:27 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 103 | $237.06 | $24,417.18 |
DisclosureSEC source: 0001127602-21-006182 · form4.xml · nonDerivative · entry 5 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,424.3789 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 283 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · derivative · entry 9 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,594 Underlying: Common Stock · 283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F6 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · derivative · entry 8 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,877 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 78 | $238.26 | $18,584.28 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634.0415 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,712.0415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 80 | $238.26 | $19,060.80 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,429.0415 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,509.0415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:27 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 283 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006182 · form4.xml · derivative · entry 8 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,754 Underlying: Common Stock · 283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F6 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:27 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 234 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006182 · form4.xml · derivative · entry 7 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,037 Underlying: Common Stock · 234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:27 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 78 | $238.26 | $18,584.28 |
DisclosureSEC source: 0001127602-21-006182 · form4.xml · nonDerivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,527.3789 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:27 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006182 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,605.3789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:27 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 64 | $238.26 | $15,248.64 |
DisclosureSEC source: 0001127602-21-006182 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,322.3789 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:27 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006182 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,386.3789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:25 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 317 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006177 · form4.xml · derivative · entry 6 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,791 Underlying: Common Stock · 317 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:25 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006177 · form4.xml · derivative · entry 5 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,108 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:25 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 93 | $238.26 | $22,158.18 |
DisclosureSEC source: 0001127602-21-006177 · form4.xml · nonDerivative · entry 4 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,472 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:25 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006177 · form4.xml · nonDerivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:25 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 87 | $238.26 | $20,728.62 |
DisclosureSEC source: 0001127602-21-006177 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,248 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:25 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006177 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:22 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006170 · form4.xml · derivative · entry 9 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,108 Underlying: Common Stock · 2,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:22 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 283 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006170 · form4.xml · derivative · entry 8 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,461 Underlying: Common Stock · 283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:22 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 234 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006170 · form4.xml · derivative · entry 7 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,744 Underlying: Common Stock · 234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:22 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 699 | $238.26 | $166,543.74 |
DisclosureSEC source: 0001127602-21-006170 · form4.xml · nonDerivative · entry 6 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667.1697 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:22 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 2,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006170 · form4.xml · nonDerivative · entry 5 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,366.1697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:22 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 85 | $238.26 | $20,252.10 |
DisclosureSEC source: 0001127602-21-006170 · form4.xml · nonDerivative · entry 4 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,013.1697 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:22 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006170 · form4.xml · nonDerivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,098.1697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:22 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 70 | $238.26 | $16,678.20 |
DisclosureSEC source: 0001127602-21-006170 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,815.1697 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:22 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006170 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,885.1697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:23 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 940 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006175 · form4.xml · derivative · entry 6 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,236 Underlying: Common Stock · 940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:23 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 780 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006175 · form4.xml · derivative · entry 5 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,176 Underlying: Common Stock · 780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2019 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2019 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:23 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 280 | $238.26 | $66,712.80 |
DisclosureSEC source: 0001127602-21-006175 · form4.xml · nonDerivative · entry 4 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,986 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:23 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006175 · form4.xml · nonDerivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:23 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 232 | $238.26 | $55,276.32 |
DisclosureSEC source: 0001127602-21-006175 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,326 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:23 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006175 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 353 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006169 · form4.xml · derivative · entry 9 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,345 Underlying: Common Stock · 353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:21 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006169 · form4.xml · derivative · entry 8 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,698 Underlying: Common Stock · 2,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.